Trial · NCT04937907
Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)
NCT04937907, Phase 2, Completed, Shanghai Children's Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS). Trials, record NCT04937907. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04937907
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)
- NCT number
- NCT04937907
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 50 participants, actual
- Lead sponsor
- Shanghai Children's Hospital
- Conditions
- Alport Syndrome, X-Linked
- Interventions
- Hydroxychloroquine Sulfate 100 milligram (mg) Tab, Benazepril hydrochloride 10 milligram (mg) Tab
- First posted
- 2021-06-24
- Last updated
- 2026-03-02
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in urinary erythrocyte count(/HP) | Baseline to maximum 48 weeks | To assess the change in urinary erythrocyte count(/HP) from baseline to week 48 for patients receiving active drug, compared to patients in Comparator Cohort. |
| Secondary | Change in 24-hour urinary protein quantity | Baseline to maximum 48 weeks | To assess the change in 24-hour urinary protein quantity from baseline to week 48 for patients receiving active drug, compared to patients in Comparator Cohort. |
| Secondary | Change in urinary albumin characterization | Baseline to maximum 48 weeks | To assess the change in urinary albumin characterization from baseline to week 48 for patients receiving active drug, compared to patients in Comparator Cohort. |
| Secondary | Change in urinary albumin to creatinine ratio | Baseline to maximum 48 weeks | To assess the change in urinary albumin to creatinine ratio from baseline to week 48 for patients receiving active drug, compared to patients in Comparator Cohort. |
| Secondary | Change in urinary erythrocyte count(urinary sediment analyzer) | Baseline to maximum 48 weeks | To assess the change in urinary erythrocyte count(urinary sediment analyzer) from baseline to week 48 for patients receiving active drug, compared to patients in Comparator Cohort. |
| Secondary | Change in eGFR from baseline | Baseline to maximum 48 weeks | To assess the increase in eGFR from baseline to week 48 for patients receiving active drug, compared to patients in Comparator Cohort. |
| Secondary | Number of participants with treatment-related adverse events | Baseline to maximum 48 weeks | Safety will be assessed by monitoring adverse events, physical examinations and clinical laboratory test through 48 weeks. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04937907
GET https://conductscience.org/api/trials/v1/NCT04937907/registered